Precision Biosciences (DTIL) EBIAT (2018 - 2025)
Precision Biosciences (DTIL) has disclosed EBIAT for 8 consecutive years, with -$21.8 million as the latest value for Q3 2025.
- On a quarterly basis, EBIAT fell 32.55% to -$21.8 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$83.6 million, a 828.37% decrease, with the full-year FY2024 number at $7.2 million, up 116.85% from a year prior.
- EBIAT was -$21.8 million for Q3 2025 at Precision Biosciences, up from -$23.5 million in the prior quarter.
- In the past five years, EBIAT ranged from a high of $32.7 million in Q2 2024 to a low of -$31.0 million in Q2 2022.
- A 5-year average of -$13.9 million and a median of -$18.7 million in 2021 define the central range for EBIAT.
- Peak YoY movement for EBIAT: soared 375.41% in 2024, then crashed 339.46% in 2025.
- Precision Biosciences' EBIAT stood at -$22.3 million in 2021, then fell by 27.81% to -$28.5 million in 2022, then skyrocketed by 52.84% to -$13.4 million in 2023, then tumbled by 32.09% to -$17.7 million in 2024, then dropped by 22.69% to -$21.8 million in 2025.
- Per Business Quant, the three most recent readings for DTIL's EBIAT are -$21.8 million (Q3 2025), -$23.5 million (Q2 2025), and -$20.6 million (Q1 2025).